Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection.

Published

Journal Article (Review)

HIV-1 is a retrovirus that integrates into host chromatin and can remain transcriptionally quiescent in a pool of immune cells. This characteristic enables HIV-1 to evade both host immune responses and antiretroviral drugs, leading to persistent infection. Upon reactivation of proviral gene expression, HIV-1 envelope (HIV-1 Env) glycoproteins are expressed on the cell surface, transforming latently infected cells into targets for HIV-1 Env-specific monoclonal antibodies (mAbs), which can engage immune effector cells to kill productively infected CD4+ T cells and thus limit the spread of progeny virus. Recent innovations in antibody engineering have resulted in novel immunotherapeutics such as bispecific dual-affinity re-targeting (DART) molecules and other bi- and trispecific antibody designs that can recognize HIV-1 Env and recruit cytotoxic effector cells to kill CD4+ T cells latently infected with HIV-1. Here, we review these immunotherapies, which are designed with the goal of curing HIV-1 infection.

Full Text

Duke Authors

Cited Authors

  • Ferrari, G; Haynes, BF; Koenig, S; Nordstrom, JL; Margolis, DM; Tomaras, GD

Published Date

  • December 2016

Published In

Volume / Issue

  • 15 / 12

Start / End Page

  • 823 - 834

PubMed ID

  • 27725635

Pubmed Central ID

  • 27725635

Electronic International Standard Serial Number (EISSN)

  • 1474-1784

International Standard Serial Number (ISSN)

  • 1474-1776

Digital Object Identifier (DOI)

  • 10.1038/nrd.2016.173

Language

  • eng